Cardiff Oncology (NASDAQ: CRDF)
Cardiff Oncology Return vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
Cardiff Oncology Company Info
Cardiff Oncology, Inc. is an oncology therapeutics company, which engages in the development of drugs that target mitosis for the treatment of various types of cancer. It is focused on developing onvansertib, a first-in-class, third-generation Polo-like Kinase 1 (PLK1) inhibitor, in combination with standard-of-care chemotherapy and targeted therapeutics. The firm's clinical programs include KRAS-Mutated Metastatic Colorectal Cancer (mCRC), Resistant Metastatic Castration-Resistant Prostate Cancer (mCRPC) and relapsed or refractory Acute Myeloid Leukemia (AML). The company was founded by Gabriel M. Cerrone, L. David Tomei, Samuil Umansky, and Hovsep Melkonyan in 1999 and is headquartered in San Diego, CA.
News & Analysis
These 2 Nasdaq Stocks Are Poised to Make Big Moves Today
These clinical-stage biotech stocks are headed in opposite directions today.
1 Cancer Stock on Buyout Watch in 2022
Cardiff Oncology is a prime takeover target heading into 2022.
Why Cardiff Oncology Shares Were Up More Than 15% on Thursday
The clinical-stage oncology specialist is getting an infusion of cash from pharmaceutical giant Pfizer.
Why Shares of Cardiff Oncology Rose on Monday
An insider buy and positive data may have boosted optimism.
Why Cardiff Oncology Ran Up 1,350% in 2020
This cancer specialist is looking to defeat the KRAS mutation.
Why Cardiff Oncology Stock Is Crashing Today
The biotech presented data from an early-stage study of its experimental colorectal cancer drug.
2 Biotech Stocks That Keep on Climbing
Here's why shares of these drugmakers seem unstoppable this year.
Why Cardiff Oncology Stock Skyrocketed Today
An analyst's bullish outlook sent the biotech stock soaring.
Valuation
Related Stocks
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.